Evommune doses first patient in Phase 2b trial of EVO756 for migraine prophylaxis

Evommune, Inc.

First patient dosed in Phase 2b trial of MRGPRX2 inhibitor EVO756 for migraine prophylaxis.
Global, randomized, double-blind, placebo-controlled, dose-ranging trial with ~330 patients over 12 weeks.
Top-line data expected in 2027; daily doses up to 100 mg being tested.
EVO756 designed to inhibit three key neuropeptides (PACAP, VIP, Substance P) via MRGPRX2.
Primary endpoint: mean change from baseline in monthly migraine days (MMD).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.